On August 31, 2023, ProMIS Neurosciences, Inc., closed the transaction. The company issued 9,945,969 common share at a price of $1.88 per unit consisting of one common share and one warrant and 954,725 pre-funded units at a price of $1.87 per unit consisting of one pre-funded warrant for the gross proceeds of $20.4 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.98 USD | +1.54% | +1.54% | +72.17% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+72.17% | 36.67M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- PMN Stock
- News ProMIS Neurosciences, Inc.
- ProMIS Neurosciences, Inc. announced that it has received $20.483758 million in funding from Affinity Asset Advisors, LLC, Ally Bridge Group, Sphera Healthcare US Inc.